Study finds BRACAnalysis vital for triple negative breast cancer patients
September 25, 2015
Head and neck cancerRecent developments in squamous cell carcinoma of the head and neck (SCCHN) have generated a paradigm shift in treatment of this disease. Data from two key surveys will quantify the role of Erbitux in the treatment of SCCHN. Erbitux is the only proven targeted therapy and - as combination treatment - a standard of care for patients with locally advanced and 1st line recurrent metastatic SCCHN.
www.GlobalCancerNewsMerck Serono is committed to developing quality resources to provide the latest information on developments in oncology. Before and during the ESMO Congress www.globalcancernews will provide information and opportunities to keep media informed about the latest data and expert opinions coming from the event. Registration takes less than a minute and visitors to the site will be able to:Book one-to-one interviews with key medical experts (first-come-first-served basis) Access hot-off-the-press news about Erbitux at the ESMO Congress Listen to leading experts put the latest data into context within the oncology landscape Download photos, animations and fact sheets
Source : Merck Serono